Life Science Connect
Life Science Connect
  • 1 214
  • 126 926
Biotech Story Time With Tal Zaks, M.D. (Part 1)
Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business of Biotech surely will. Tal is now leading a new mRNA-centric startup called Exsilio Therapeutics, which Advancing RNA's Anna Rose Welch and I dig into in part two of our talk with Tal, slated for release in early January. Yep, Story Time With Tal is so good, we doubled up the episodes with him. Tune in for insight from the early days of mRNA that you probably haven't heard before, and stay for a glimpse of its future role in therapeutics at Exsilio with one of the foremost thinkers in the space.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: www.linkedin.com/in/matthewpillar/
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4
Spotify - open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA
TH-cam - th-cam.com/play/PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb.html
มุมมอง: 286

วีดีโอ

Can Gene Therapy Be the Solution for CHF with AskBio's Dr. Lothar Roessig
มุมมอง 2916 ชั่วโมงที่ผ่านมา
Cell & Gene: The Podcast Host Erin Harris talks to Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) about the biggest challenges in developing gene therapies for cardiovascular diseases, specifically congestive heart failure (CHF). They discuss AB-1002, the gene therapy the company is developing for the treatment of ...
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.
มุมมอง 145วันที่ผ่านมา
This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing respo...
What Can Biotech Leaders Learn From Gates MRI?
มุมมอง 2314 วันที่ผ่านมา
Gates MRI's Dr. Claire Wagner explains how collaboration is key to success for nonprofits and biotech companies alike. An excerpt from "Serving The Underserved With Gates MRI's Claire Wagner, M.D." - check out the full video at www.bioprocessonline.com/doc/serving-the-underserved-with-gates-mri-s-claire-wagner-m-d-0001 #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - pod...
Gates MRI’s Claire Wagner On The Fight Against TB
มุมมอง 414 วันที่ผ่านมา
Dr. Claire Wagner, head of CMC at Gates MRI, describes her journey from anthropologist to MD to nonprofit leader and the current state of TB research. An excerpt from "Serving The Underserved With Gates MRI's Claire Wagner, M.D." - check out the full video at www.bioprocessonline.com/doc/serving-the-underserved-with-gates-mri-s-claire-wagner-m-d-0001 #businessofbiotech #biopharma #biotech Subsc...
What’s Next For Adaptimmune?
มุมมอง 4514 วันที่ผ่านมา
Adrian Rawcliffe offers career advice to aspiring biotech leaders and previews Adaptimmune’s pipeline now that Tecelra has been approved by the FDA. An excerpt from "T-Cells For The Win With Adaptimmune's Adrian Rawcliffe" - check out the full video at www.bioprocessonline.com/doc/t-cells-for-the-win-with-adaptimmune-s-adrian-rawcliffe-0001 #businessofbiotech #biopharma #biotech Subscribe to th...
What Makes The Cell Therapy Business Model Unique?
มุมมอง 1614 วันที่ผ่านมา
Adaptimmune’s Adrian Rawcliffe discusses the current and emerging cell therapy landscape and the path to commercialization. An excerpt from "T-Cells For The Win With Adaptimmune's Adrian Rawcliffe" - check out the full video at www.bioprocessonline.com/doc/t-cells-for-the-win-with-adaptimmune-s-adrian-rawcliffe-0001 #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - podcas...
Should Cell Therapy Companies Outsource Or Build Manufacturing Facilities?
มุมมอง 2214 วันที่ผ่านมา
Adaptimmune’s Adrian Rawcliffe weighs in on the make vs. buy debate and why his company chose to build in-house manufacturing capabilities. An excerpt from "T-Cells For The Win With Adaptimmune's Adrian Rawcliffe" - check out the full video at www.bioprocessonline.com/doc/t-cells-for-the-win-with-adaptimmune-s-adrian-rawcliffe-0001 #businessofbiotech #biopharma #biotech Subscribe to the podcast...
Adaptimmune’s Adrian Rawcliffe On Changing Our Relationship With Cancer
มุมมอง 3914 วันที่ผ่านมา
Adaptimmune’s Tecelra recently became the first TCR cell therapy approved in the US, and CEO Adrian Rawcliffe explains why cell therapies could transform all cancer treatments. An excerpt from "T-Cells For The Win With Adaptimmune's Adrian Rawcliffe" - check out the full video at www.bioprocessonline.com/doc/t-cells-for-the-win-with-adaptimmune-s-adrian-rawcliffe-0001 #businessofbiotech #biopha...
Balancing User-Related Risk Assessments With Use-Enabling Device Enhancements
มุมมอง 314 วันที่ผ่านมา
Can a diligent focus on patient safety during combination product development inadvertently lead to missed opportunities for device use enhancements? In this segment of the Drug Deliver Leader Live! event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, discusses ways to keep the organization focused on developing quali...
URRA And UFMEA: Together Or Separate For Combination Products?
มุมมอง 414 วันที่ผ่านมา
Both uFMEA (Use Failure Mode Effects Analysis) and URRA (Use-Related Risk Analysis) tools are available during combination product development for conducting risk assessments related to human factors. In this segment of the Drug Deliver Leader Live! event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, and Shannon Host...
Why Start A URRA Early In Combination Product Design?
มุมมอง 414 วันที่ผ่านมา
Both a URRA (Use-Related Risk Analysis) and IFU (Instructions for Use) can help to mitigate the risk of user misuse of a combination product. In this segment of the Drug Deliver Leader Live! event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Shannon Hoste, chief scientific officer at Pathway for Patient Health, offers rationale for starting and conducting the URRA ahead of deve...
When And How To Use A UFMEA During Device Design
มุมมอง 514 วันที่ผ่านมา
When and how might using a uFMEA (Use Failure Mode Effects Analysis) tool benefit biopharma companies addressing regulatory expectations for analyses of risk and/or human factors? In this segment of the Drug Deliver Leader Live! event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, and Shannon Hoste, chief scientific o...
What Types Of Products Are Assessed With A URRA?
14 วันที่ผ่านมา
What types of products in development may need to be assessed in accordance with the FDA’s URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Deliver Leader Live! event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, describes several common scenarios that illustrate when a URRA approach may or may ...
The Regulatory Intent Of A URRA For Combination Products
มุมมอง 414 วันที่ผ่านมา
To what extent are approaches to conducting risk assessments specified in the FDA URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Deliver Leader Live! event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Shannon Hoste, chief scientific officer at Pathway for Patient Health, offers context-setting perspective on what FDA is looking for when reviewing URRA co...
Virtual Pharma Expo 2025 | Revolutionizing Pharma Equipment Selection
มุมมอง 2414 วันที่ผ่านมา
Virtual Pharma Expo 2025 | Revolutionizing Pharma Equipment Selection
Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski
มุมมอง 13514 วันที่ผ่านมา
Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski
Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rakhit
มุมมอง 11521 วันที่ผ่านมา
Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rakhit
What Does 2025 (And Beyond) Hold For The RNA-LNP Space?
มุมมอง 1021 วันที่ผ่านมา
What Does 2025 (And Beyond) Hold For The RNA-LNP Space?
CMC Innovations Worth Watching In The RNA-LNP Space
มุมมอง 221 วันที่ผ่านมา
CMC Innovations Worth Watching In The RNA-LNP Space
What Innovations Could Help Us Overcome Preclinical Model Limitations for RNA-LNPs?
มุมมอง 621 วันที่ผ่านมา
What Innovations Could Help Us Overcome Preclinical Model Limitations for RNA-LNPs?
R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery
มุมมอง 1221 วันที่ผ่านมา
R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery
In What Ways Are We Underestimating LNP Complexity Today?
มุมมอง 2021 วันที่ผ่านมา
In What Ways Are We Underestimating LNP Complexity Today?
Goldilocks & The 3…CQAs? Finding “Just Right” With LNP Optimization
มุมมอง 421 วันที่ผ่านมา
Goldilocks & The 3…CQAs? Finding “Just Right” With LNP Optimization
What Have We Learned About Our LNP’s Function In Vitro In 2024?
มุมมอง 1721 วันที่ผ่านมา
What Have We Learned About Our LNP’s Function In Vitro In 2024?
Advancements In LNP CMC: What Are The Current “Known Knowns”?
มุมมอง 921 วันที่ผ่านมา
Advancements In LNP CMC: What Are The Current “Known Knowns”?
Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D.
มุมมอง 11521 วันที่ผ่านมา
Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D.
Biopolitics With Allan Shaw
มุมมอง 112หลายเดือนก่อน
Biopolitics With Allan Shaw
Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene
มุมมอง 32หลายเดือนก่อน
Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene
Fed Funding: Creative Capital Generation With James Thomas Coates, Ph.D.
มุมมอง 105หลายเดือนก่อน
Fed Funding: Creative Capital Generation With James Thomas Coates, Ph.D.

ความคิดเห็น

  • @Superflow66
    @Superflow66 หลายเดือนก่อน

    Amazing stuff. I’m a shareholder and appreciate the info.

  • @Syed________6686
    @Syed________6686 3 หลายเดือนก่อน

    What about type 2 !!!!!!

  • @JudsonDean-y7s
    @JudsonDean-y7s 3 หลายเดือนก่อน

    Thomas Matthew Rodriguez Elizabeth Taylor Melissa

  • @HuttEdwiin
    @HuttEdwiin 3 หลายเดือนก่อน

    Lewis Charles Moore Gary Young Timothy

  • @TeriHamilton-o4e
    @TeriHamilton-o4e 4 หลายเดือนก่อน

    Harris Brian Clark Linda Hall Steven

  • @RichardCroce
    @RichardCroce 4 หลายเดือนก่อน

    You need to call palantir, they will help you get to the next level. Palantir is the best product for your journey!! Gl

  • @VasudhaivKutumbakam108
    @VasudhaivKutumbakam108 4 หลายเดือนก่อน

    Useful info

  • @VasudhaivKutumbakam108
    @VasudhaivKutumbakam108 4 หลายเดือนก่อน

    Very Useful

  • @jaqueitch
    @jaqueitch 5 หลายเดือนก่อน

    Amazing technology - so close to prime time!!

  • @jerm184
    @jerm184 6 หลายเดือนก่อน

    Why she sold

    • @zaheraldik5016
      @zaheraldik5016 6 หลายเดือนก่อน

      Such a mystery !

  • @okiedokie1238
    @okiedokie1238 9 หลายเดือนก่อน

    Is it possible to access this stream in it's entirety? This channel is a gem!

  • @lw1zfog
    @lw1zfog 10 หลายเดือนก่อน

    ‘For us, therefore, we’re really taking that leap - us as company, Bayer, in cell and gene therapy, which to me is one of these examples where really we’re going to make a difference, hopefully, moving forward. Ultimately the mRNA vaccines are an example for that - cell and gene therapy - I always like to say that if we had surveyed two years ago in the public, “would you be willing to take a gene or cell therapy and inject it into your body” - we would have had probably a 95% refusal rate. I think this pandemic has also opened many people’s eyes to innovation in a way that was maybe not possible before.’ - Bayer Executive Stefan Oelrich, in a speech at the World Health Summit, October 2021.

  • @Mr.Funny8484
    @Mr.Funny8484 11 หลายเดือนก่อน

    Biotech industry is engaged in production of only mAbs & earning money and not altering the microbiom.

  • @maxharmify
    @maxharmify 11 หลายเดือนก่อน

    GOOD JOB!

  • @darnellamero1168
    @darnellamero1168 11 หลายเดือนก่อน

    My son is off to sickkids hospital in Toronto in 2 weeks to receive his car-t cell treatment. He had ALL leukimia nearly 7 years ago and he relapsed. He is the the sweetest down syndrome kid you could ever meet. I can not thank Mr Carl June enough for giving us the oppurtunity to see our son live a normal life. If Dr. june and his team does not win a nobel prize for this, then the world needs a reset. This man is a God sent angel for sure. It would be a pleasure to shake this mans hand.

  • @alvares893
    @alvares893 ปีที่แล้ว

    Gracias, esperamos pronto buenas noticias Afectado pde6a

  • @KarenLewis-mu1ud
    @KarenLewis-mu1ud ปีที่แล้ว

    Foreshadowing of his current vibrant presidential campaign.

  • @AdamBicycle
    @AdamBicycle ปีที่แล้ว

    Very on point questions, insightful.

  • @rakeshsharma-dz7so
    @rakeshsharma-dz7so ปีที่แล้ว

    hello sir thanks lot for this awesome conversation (jackpot of knowledge).

  • @southousee
    @southousee ปีที่แล้ว

    This really was completely useless

  • @BioMedUSA
    @BioMedUSA ปีที่แล้ว

    Very refreshing interview! Nice to hear a CEO of a biotech talk like a regular person excited about her company compared to these other CEO's I have listened to recently who drone on and sound like they are reading a script and a boring one at that. Dr. Sullivan sounds highly motivated and I can imagine it is / will be relatively easy for her to close future deals with large pharma. And her experience and great success with Springworks Therapeutics should engender confidence in her ability to run PYXS. PYXS presently trading at less than half of their cash value and looks to be an incredible bargain at the present stock price!

  • @FightBackAgainstDiabetes
    @FightBackAgainstDiabetes ปีที่แล้ว

    *You Did Not Choose To Be Classified As Diabetic, But You Can Choose To Fight Back Against Diabetes* 💪

    • @mehmetalikutlu3513
      @mehmetalikutlu3513 ปีที่แล้ว

      Cocuklara uygulanırmi ne kadar olur fiyatı sizce

    • @kingshuksahu5159
      @kingshuksahu5159 ปีที่แล้ว

      Eai comment ta kora bandho kor baler...

  • @dexion12
    @dexion12 ปีที่แล้ว

    Incredibly great interview. Now a huge Cidera and Matt Pillar fan.

  • @FolakeBamigboye
    @FolakeBamigboye ปีที่แล้ว

    Times used to be very Challenging, I had the worst days of my life living with Type 2 diabetes, I appreciate you so much Dr Igudia, You have restored me my life that was lost already . Thank you so much for curing me of my diabetes with your natural Herbs 😊

  • @HotBodzLatino
    @HotBodzLatino ปีที่แล้ว

    I would really like to be a patient for this clinic trial as I am a T1D for 11 1/2 yrs

    • @durgabisheti1733
      @durgabisheti1733 ปีที่แล้ว

      How is the treatment? Are you satisfied of this treatment? Now are you independent from insulin injection? Please reply me it's very important

  • @LovePeace2025
    @LovePeace2025 ปีที่แล้ว

    Nothing is done since the interview. Telling story ain't cut it, it is time to execute it.

  • @SamEbby
    @SamEbby ปีที่แล้ว

    This dude said a whole lot of nothing . He can talk forever and say absolutely nothing

  • @barrybentley8066
    @barrybentley8066 2 ปีที่แล้ว

    No cure no cure no cure 😢

    • @nwc3270
      @nwc3270 ปีที่แล้ว

      They have a cure, 3 people are insulin free, 1 lady has been insulin free for over 2 years and counting, just have to get the fda to fast track what there doing

    • @jayalakshmi2959
      @jayalakshmi2959 ปีที่แล้ว

      Hi sir iam living to one of belive , iam counting for days when will stem cell cure diabets

  • @mikeliu3475
    @mikeliu3475 2 ปีที่แล้ว

    Congratulations Michelle and your team for the great achievements within the short period of time!

  • @TheAmitrajpurohit
    @TheAmitrajpurohit 2 ปีที่แล้ว

    All the blessings and powers to you, God bless. All T1D people are going to thank and bless you throughout their lives.

  • @pihugupta6764
    @pihugupta6764 2 ปีที่แล้ว

    Which Hospital Available Stem cell therepy T1dibetes in India...

    • @savathi.v8139
      @savathi.v8139 ปีที่แล้ว

      Go to dr .sagar jawala jalgon mhararastra

  • @babayt3932
    @babayt3932 2 ปีที่แล้ว

    God help you, God help you, I saw that you are working for us with DT1, we are not living, we are surviving, dependent on the insulin that saved us, please, please, help, respect

  • @christinekho8832
    @christinekho8832 2 ปีที่แล้ว

    A very much oversold stock...IO102-103 with 3 years survival probability of >70%..this is much better than recently approved opduolag and nivo/ipi combo

  • @Jamesfoleyjr
    @Jamesfoleyjr 2 ปีที่แล้ว

    silencing rnai is a Reversible and natural occurrence... homeostatic medicine. Silence, the abnormal protein and let the body heal itself.

  • @rj-fu8rz
    @rj-fu8rz 2 ปีที่แล้ว

    It is nice to see this Nobel- prize winning technology leading to drugs….very promising!

  • @rosewillsonfred9752
    @rosewillsonfred9752 2 ปีที่แล้ว

    I want to Share This testimony. And also thanking God For Saving my life Through #DrAlaka Who Cures All kinds Of Deadly Virus. With is Gift Of Herbal remedy. Want to say a big thanks to you #DrAlaka for saving me from Anemia Virus that I have suffer for long Now with your herbal Remedy. God Bless you Sir. Add on TH-cam @ #drAlaka or through👉th-cam.com/channels/mkfwnFpXrrsHSxXmdgmCLg.html .....

  • @thunderdrumandbass
    @thunderdrumandbass 2 ปีที่แล้ว

    this channel adds straight value. i wish i could listen live. thank you so much for uploading this

  • @paulhampel8084
    @paulhampel8084 2 ปีที่แล้ว

    I'm surprise this discussion viewed LNP mRNA as full mRNA only. Moderna's current Personalized Cancer Vaccine mRNA-4157 Phase 2 focuses on neoantigens cleaved by proteasome in the cell. The Neoantigen Protein Chain does not seem like a major size problem. I think this discussion was not very balanced. I see the value of Car-T and cas9 but I'm not sure they compete with LNP mRNA approaches that much.

  • @Mr.Moderator
    @Mr.Moderator 2 ปีที่แล้ว

    They will get bought out or bleed out. Hope mgmt makes right decision here.

  • @phillyarrowood7868
    @phillyarrowood7868 2 ปีที่แล้ว

    ƤRO𝓂O𝕤ᗰ 🙂

  • @insidethemind434
    @insidethemind434 2 ปีที่แล้ว

    What is the name of that documentary?

  • @Frank020
    @Frank020 2 ปีที่แล้ว

    I'm Holden, but not golden. 🌝 . Let's moon this B word, my queens of the biosciences.💗...😁🌝

  • @СветланаАтрошенко-й4м
    @СветланаАтрошенко-й4м 2 ปีที่แล้ว

    th-cam.com/video/K4pYemga4Cs/w-d-xo.html ?

  • @jasondavis2810
    @jasondavis2810 2 ปีที่แล้ว

    Great discussion

  • @Havana1975xx
    @Havana1975xx 2 ปีที่แล้ว

    Thank you great work

  • @craigmosolowski4663
    @craigmosolowski4663 2 ปีที่แล้ว

    I predict a Nobel Prize for Dr. Laura Niklason!

  • @luckyea7
    @luckyea7 2 ปีที่แล้ว

    The Russian Sputnik V vaccine demonstrates effective protection against the COVID-19 omicron strain and a higher antibody titer compared to two injections of the American Pfizer vaccine. This is evidenced by the results of a study by the Spallanzani Institute in Italy, the results of which were published in the medical journal Vaccines, the Gamaleya National Research Center for Epidemiology and Microbiology reported. It is known that the titer of virus-neutralizing antibodies to omicron in Sputnik V turned out to be 2.1 times higher in general and 2.6 times higher three months after vaccination. Thus, 74.2 percent of all blood serum samples vaccinated with the domestic drug neutralized omicron (against 56.9 percent from Pfizer). Experts found that Sputnik V generates a stronger response due to a wider range of virus-neutralizing antibodies, a heterogeneous vaccine scheme, and a higher degree of infection imitation by the adenoviral platform. It is noted that the study was conducted under equal laboratory conditions at the Spallanzani Institute on the basis of comparable serum samples from individuals vaccinated with Sputnik V and Pfizer with similar levels of IgG antibodies and virus-neutralizing activity to the original strain registered in Wuhan, China.

  • @alesbuxbaum9616
    @alesbuxbaum9616 2 ปีที่แล้ว

    The Ring Therapeutics has been facing many scientific challenges over the years in regards of generating the human anellovirus therapeutic vectors; human anelloviruses seem to be some kind of evolving viruses or week like viruses - anellovirueses do not have endogenous-own viral replicase proteins, a known DNA conserved origin of replication stem loop, and indeed they form very unstable capsid virions. The potential therapeutic payload of a recombinant TTMV-Anellovirus vector may be very limited around 2000bp in size. Here, we talk about a possibility of the first generation anellovirus vectors based on scientific academy papers published many years ago….

  • @David-tq9bi
    @David-tq9bi 2 ปีที่แล้ว

    HAHAAHAH f... your Ideas, you can not realize shit. You don't Value your Investors, 5 Times RS until now. Paying yourself astronomical Paychecks every year out and in 15 years Company achieved nothing!!!

  • @Imran-eo9vt
    @Imran-eo9vt 2 ปีที่แล้ว

    Reaching cure of Type 1 Diabetes will be great service for Humanity. Millions of people are waiting for cure.